Literature DB >> 32030296

What is synchronous oligometastatic non-small cell lung cancer?

Chan-Kyung Jane Cho1, Balamurugan A Vellayappan2, Emma M Dunne3, Shankar Siva4, Mitchell Liu5, Alexander V Louie6, Gerard G Hanna4, Simon S Lo1.   

Abstract

Entities:  

Year:  2019        PMID： 32030296      PMCID： PMC6988042          DOI： 10.21037/jtd.2019.12.44

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  12 in total

1.  Cancer statistics, 2019.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2019-01-08       Impact factor: 508.702

2.  Defining Synchronous Oligometastatic Non-Small Cell Lung Cancer: A Systematic Review.

Authors:  Niccolò Giaj-Levra; Matteo Giaj-Levra; Valerie Durieux; Silvia Novello; Benjamin Besse; Baktiar Hasan; Lizza E Hendriks; Antonin Levy; Anne-Marie C Dingemans; Thierry Berghmans
Journal:  J Thorac Oncol       Date:  2019-06-11       Impact factor: 15.609

3.  Outcomes of a Highly Selective Surgical Approach to Oligometastatic Lung Cancer.

Authors:  Katelyn K Johnson; Joshua E Rosen; Michelle C Salazar; Daniel J Boffa
Journal:  Ann Thorac Surg       Date:  2016-06-23       Impact factor: 4.330

4.  Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases: long-term results of a prospective phase II trial (Nct01282450).

Authors:  Dirk De Ruysscher; Rinus Wanders; Angela van Baardwijk; Anne-Marie C Dingemans; Bart Reymen; Ruud Houben; Gerben Bootsma; Cordula Pitz; Linda van Eijsden; Wiel Geraedts; Brigitta G Baumert; Philippe Lambin
Journal:  J Thorac Oncol       Date:  2012-10       Impact factor: 15.609

Review 5.  Strategies and technical challenges for imaging oligometastatic disease: Recommendations from the European Organisation for Research and Treatment of Cancer imaging group.

Authors:  Nandita M deSouza; Yan Liu; Arturo Chiti; Daniela Oprea-Lager; Géraldine Gebhart; Bernard E Van Beers; Ken Herrmann; Frederic E Lecouvet
Journal:  Eur J Cancer       Date:  2018-01-10       Impact factor: 9.162

6.  The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer.

Authors:  Peter Goldstraw; Kari Chansky; John Crowley; Ramon Rami-Porta; Hisao Asamura; Wilfried E E Eberhardt; Andrew G Nicholson; Patti Groome; Alan Mitchell; Vanessa Bolejack
Journal:  J Thorac Oncol       Date:  2016-01       Impact factor: 15.609

7.  Special treatment issues in non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.

Authors:  Benjamin D Kozower; James M Larner; Frank C Detterbeck; David R Jones
Journal:  Chest       Date:  2013-05       Impact factor: 9.410

8.  Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study.

Authors:  Daniel R Gomez; George R Blumenschein; J Jack Lee; Mike Hernandez; Rong Ye; D Ross Camidge; Robert C Doebele; Ferdinandos Skoulidis; Laurie E Gaspar; Don L Gibbons; Jose A Karam; Brian D Kavanagh; Chad Tang; Ritsuko Komaki; Alexander V Louie; David A Palma; Anne S Tsao; Boris Sepesi; William N William; Jianjun Zhang; Qiuling Shi; Xin Shelley Wang; Stephen G Swisher; John V Heymach
Journal:  Lancet Oncol       Date:  2016-10-24       Impact factor: 41.316

9.  Comparison of Survival Rates After a Combination of Local Treatment and Systemic Therapy vs Systemic Therapy Alone for Treatment of Stage IV Non-Small Cell Lung Cancer.

Authors:  Johannes Uhlig; Meaghan Dendy Case; Justin D Blasberg; Daniel J Boffa; Anne Chiang; Scott N Gettinger; Hyun S Kim
Journal:  JAMA Netw Open       Date:  2019-08-02

10.  Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial.

Authors:  Puneeth Iyengar; Zabi Wardak; David E Gerber; Vasu Tumati; Chul Ahn; Randall S Hughes; Jonathan E Dowell; Naga Cheedella; Lucien Nedzi; Kenneth D Westover; Suprabha Pulipparacharuvil; Hak Choy; Robert D Timmerman
Journal:  JAMA Oncol       Date:  2018-01-11       Impact factor: 31.777
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.